Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Novo Nordisk A/S (NYSE:NVO) is one of the stocks that Jim Cramer shed light on. A caller asked about the stock’s status, and ...

Dr. Reddy’s Laboratories (NYSE:RDY) is preparing to launch a generic version of semaglutide, the active ingredient in Novo ...

The drugmaker plans to launch Semaglutide in 87 countries next year, including those where patents are expiring and emerging ...

Dr Reddy's reported Rs 1,417 crore net profit in Q1 FY26, driven by new launches and price hikes; firm outlines global ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...